Fujifilm to Invest $2B in US Manufacturing Site

Fujifilm Corporation is investing more than $2 billion to establish a new large-scale cell culture production site in the U.S. to accelerate the growth of its biopharmaceutical contract development and manufacturing business.

Fujifilm Diosynth Biotechnologies, a subsidiary of Fujifilm Corporation, with development and manufacturing facilities across the U.S., UK, and Denmark will operate the new facility.

This new facility will offer large-scale cell culture manufacturing of bulk drug substance with 8 x 20,000L bioreactors (physical volume), with the potential to expand and add a further 24 x 20,000L bioreactors based on market demand. In addition to drug substance manufacture, the facility will also provide commercial scale, automated fill-finish and assembly, packaging and labeling services. The new site will be built within the vicinity of an existing Fujifilm site, and is scheduled to begin operations in the spring of 2025.

“The U.S. is the world’s biggest market for biopharmaceuticals. I am pleased that through this large investment in the U.S.A we are able to support the development and manufacturing of new drugs that can help fulfill unmet medical needs,” said Kenji Sukeno, president of Fujifilm Corporation. “Fujifilm will continue to promote human health and support the progress of the healthcare industry by using our cutting-edge technology and advanced facilities to provide a stable supply of high-quality biopharmaceuticals.”

Fujifilm is actively investing to enhance and grow its end-to-end service offerings across all of its Bio CDMO sites. In June, Fujifilm Corporation invested $928 million in Fujifilm Diosynth Biotechnologies’ Hillerød, Denmark site to double its large-scale cell culture manufacturing capacity and add commercial scale drug product production capabilities.

“We are leveraging our strengths in process development and manufacturing for a wide range of biopharmaceuticals such as antibodies, recombinant proteins, gene therapies and vaccines,” said Martin Meeson, chief executive officer, Fujifilm Diosynth Biotechnologies. “We are uniquely placed to support our customer supply chain needs providing end to end services from small to large scale bulk drug substance production, through to fill-finish and final packing.”

Fujifilm has set a target to achieve an annual revenue of $1.9 billion for its Bio CDMO business by fiscal year ending March 2025. Beyond fiscal year ending March 2026, Fujifilm expects this latest investment to boost the annual growth rate of its Bio CDMO Business to 20%, greatly exceeding market projections. Going forward, Fujifilm will continue to contribute to the healthcare industry by providing a stable supply of high-quality pharmaceuticals.